New imaging agent could reveal hidden prostate cancer
NCT ID NCT05245006
First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This early-phase study tests a new PET imaging agent (89Zr-DFO-YS5) designed to find a protein called CD46 on prostate cancer cells in men with advanced, treatment-resistant prostate cancer. About 30 participants will receive the agent and undergo PET scans to see if it can accurately detect tumors. The goal is to improve imaging for this aggressive cancer and help develop better treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.